Top Suppliers:I want be here


41270-96-6

41270-96-6 structure
41270-96-6 structure
  • Name: 4-IPP
  • Chemical Name: 4-Iodo-6-phenylpyrimidine
  • CAS Number: 41270-96-6
  • Molecular Formula: C10H7IN2
  • Molecular Weight: 282.08000
  • Catalog: Research Areas Metabolic Disease
  • Create Date: 2017-09-01 01:09:03
  • Modify Date: 2024-01-13 12:51:23
  • 4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF)[1].

Name 4-Iodo-6-phenylpyrimidine
Synonyms 4-Jod-2-methyl-6-nitro-anilin
iodomethylnitroaniline
4-iodo-2-methyl-6-nitro-aniline
4-iodo-6-phenyl-pyrimidine
4-iodo-2-methyl-6-nitrobenzenamine
4-iodo-6-methyl-2-nitroaniline
5-Jod-3-nitro-2-amino-toluol
Description 4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF)[1].
Related Catalog
Target

MIF[1]

In Vitro 4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity[1]. 4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes[1]. 4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation[1]. 4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner[1]. 4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption [1]. Cell Cytotoxicity Assay[1] Cell Line: BMMs Concentration: 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM Incubation Time: 24 hours, 72 hours Result: Inhibited osteoclastogenesis in a dose-dependent manner. Western Blot Analysis[1] Cell Line: BMMs Concentration: 5 μM,10 μM, 20 μM Incubation Time: 1 day, 3 days, 5 days Result: Inhibited RANKL-induced osteoclast differentiation and bone resorption.
In Vivo 4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation[1]. Animal Model: 8-weeks-old C57BL/6J male mice[1] Dosage: 1 mg/kg, 5 mg/kg Administration: Intraperitoneal injection; every 2 days; for 8 weeks Result: Alleviated OVX-induced osteoporosis.
References

[1]. Zheng L, et al. Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF-κB signaling pathway. FASEB J. 2019 Jun;33(6):7667-7683.

Density 1.728±0.06 g/cm3
Boiling Point 380.2±30.0 °C
Molecular Formula C10H7IN2
Molecular Weight 282.08000
Exact Mass 281.96500
PSA 25.78000
LogP 2.74820
Storage condition -20°C
Symbol GHS05 GHS07
GHS05, GHS07
Signal Word Danger
Hazard Statements H302-H315-H318-H335
Precautionary Statements P261-P280-P305 + P351 + P338
Hazard Codes C
RIDADR NONH for all modes of transport